Cargando…
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829205/ https://www.ncbi.nlm.nih.gov/pubmed/33521604 http://dx.doi.org/10.1016/j.isci.2021.102054 |
_version_ | 1783641138227314688 |
---|---|
author | Mohandas, Sreelekshmy Yadav, Pragya D. Shete-Aich, Anita Abraham, Priya Vadrevu, Krishna Mohan Sapkal, Gajanan Mote, Chandrashekhar Nyayanit, Dimpal Gupta, Nivedita Srinivas, Vellimedu Kannappa Kadam, Manoj Kumar, Abhimanyu Majumdar, Triparna Jain, Rajlaxmi Deshpande, Gururaj Patil, Savita Sarkale, Prasad Patil, Deepak Ella, Raches Prasad, Sai D. Sharma, Sharda Ella, Krishna M. Panda, Samiran Bhargava, Balram |
author_facet | Mohandas, Sreelekshmy Yadav, Pragya D. Shete-Aich, Anita Abraham, Priya Vadrevu, Krishna Mohan Sapkal, Gajanan Mote, Chandrashekhar Nyayanit, Dimpal Gupta, Nivedita Srinivas, Vellimedu Kannappa Kadam, Manoj Kumar, Abhimanyu Majumdar, Triparna Jain, Rajlaxmi Deshpande, Gururaj Patil, Savita Sarkale, Prasad Patil, Deepak Ella, Raches Prasad, Sai D. Sharma, Sharda Ella, Krishna M. Panda, Samiran Bhargava, Balram |
author_sort | Mohandas, Sreelekshmy |
collection | PubMed |
description | The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152C in Syrian hamsters. Three dose vaccination regimes with vaccine candidates induced significant titers of SARS-CoV-2-specific IgG and neutralizing antibodies. BBV152A and BBV152B vaccine candidates remarkably generated a quick and robust immune response. Post-SARS-CoV-2 infection, vaccinated hamsters did not show any histopathological changes in the lungs. The protection of the hamster was evident by the rapid clearance of the virus from lower respiratory tract, reduced virus load in upper respiratory tract, absence of lung pathology, and robust humoral immune response. These findings confirm the immunogenic potential of the vaccine candidates and further protection of hamsters challenged with SARS-CoV-2. Of the three candidates, BBV152A showed the better response. |
format | Online Article Text |
id | pubmed-7829205 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-78292052021-01-26 Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model Mohandas, Sreelekshmy Yadav, Pragya D. Shete-Aich, Anita Abraham, Priya Vadrevu, Krishna Mohan Sapkal, Gajanan Mote, Chandrashekhar Nyayanit, Dimpal Gupta, Nivedita Srinivas, Vellimedu Kannappa Kadam, Manoj Kumar, Abhimanyu Majumdar, Triparna Jain, Rajlaxmi Deshpande, Gururaj Patil, Savita Sarkale, Prasad Patil, Deepak Ella, Raches Prasad, Sai D. Sharma, Sharda Ella, Krishna M. Panda, Samiran Bhargava, Balram iScience Article The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152C in Syrian hamsters. Three dose vaccination regimes with vaccine candidates induced significant titers of SARS-CoV-2-specific IgG and neutralizing antibodies. BBV152A and BBV152B vaccine candidates remarkably generated a quick and robust immune response. Post-SARS-CoV-2 infection, vaccinated hamsters did not show any histopathological changes in the lungs. The protection of the hamster was evident by the rapid clearance of the virus from lower respiratory tract, reduced virus load in upper respiratory tract, absence of lung pathology, and robust humoral immune response. These findings confirm the immunogenic potential of the vaccine candidates and further protection of hamsters challenged with SARS-CoV-2. Of the three candidates, BBV152A showed the better response. Elsevier 2021-01-09 /pmc/articles/PMC7829205/ /pubmed/33521604 http://dx.doi.org/10.1016/j.isci.2021.102054 Text en © 2021 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Mohandas, Sreelekshmy Yadav, Pragya D. Shete-Aich, Anita Abraham, Priya Vadrevu, Krishna Mohan Sapkal, Gajanan Mote, Chandrashekhar Nyayanit, Dimpal Gupta, Nivedita Srinivas, Vellimedu Kannappa Kadam, Manoj Kumar, Abhimanyu Majumdar, Triparna Jain, Rajlaxmi Deshpande, Gururaj Patil, Savita Sarkale, Prasad Patil, Deepak Ella, Raches Prasad, Sai D. Sharma, Sharda Ella, Krishna M. Panda, Samiran Bhargava, Balram Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model |
title | Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model |
title_full | Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model |
title_fullStr | Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model |
title_full_unstemmed | Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model |
title_short | Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model |
title_sort | immunogenicity and protective efficacy of bbv152, whole virion inactivated sars- cov-2 vaccine candidates in the syrian hamster model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829205/ https://www.ncbi.nlm.nih.gov/pubmed/33521604 http://dx.doi.org/10.1016/j.isci.2021.102054 |
work_keys_str_mv | AT mohandassreelekshmy immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT yadavpragyad immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT sheteaichanita immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT abrahampriya immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT vadrevukrishnamohan immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT sapkalgajanan immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT motechandrashekhar immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT nyayanitdimpal immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT guptanivedita immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT srinivasvellimedukannappa immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT kadammanoj immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT kumarabhimanyu immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT majumdartriparna immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT jainrajlaxmi immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT deshpandegururaj immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT patilsavita immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT sarkaleprasad immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT patildeepak immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT ellaraches immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT prasadsaid immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT sharmasharda immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT ellakrishnam immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT pandasamiran immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel AT bhargavabalram immunogenicityandprotectiveefficacyofbbv152wholevirioninactivatedsarscov2vaccinecandidatesinthesyrianhamstermodel |